The adverse impact of a gain in chromosome 1q on the prognosis of multiple myeloma treated with bortezomib-based regimens: A retrospective single-center study in China.

Qingxiao Chen,Xiaoyan Han,Gaofeng Zheng,Yang Yang,Yi Li,Enfan Zhang,Li Yang,Mengmeng Dong,Donghua He,Jingsong He,Zhen Cai

Frontiers in oncology（2022）

引用 1|浏览10

暂无评分

摘要

+1q is associated with a higher tumor burden and correlated with the occurrence of del(13q) and IgH rearrangement at diagnosis. In the era of novel agents, +1q still significantly affects PFS and OS.

查看译文

关键词

1q gain,bortezomib,chinese population,myeloma,single center

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要